Analyst Expectations For Immunocore Hldgs's Future

Ratings for Immunocore Hldgs IMCR were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Immunocore Hldgs, presenting an average target of $63.0, a high estimate of $100.00, and a low estimate of $35.00. Observing a downward trend, the current average is 20.25% lower than the prior average price target of $79.00.

Investigating Analyst Ratings: An Elaborate Study

A clear picture of Immunocore Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Immunocore Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Immunocore Hldgs compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Immunocore Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Immunocore Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Immunocore Hldgs analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Immunocore Hldgs: A Closer Look

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Financial Insights: Immunocore Hldgs

Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.

Positive Revenue Trend: Examining Immunocore Hldgs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.74% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Immunocore Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 10.89%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Immunocore Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of 2.37%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Immunocore Hldgs's ROA excels beyond industry benchmarks, reaching 0.83%. This signifies efficient management of assets and strong financial health.

Debt Management: Immunocore Hldgs's debt-to-equity ratio surpasses industry norms, standing at 1.27. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Analyst Ratings: Simplified

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.